Filing Details
Design Therapeutics, Inc. (NASDAQ:DSGN) filed a Form 8-K with the Securities and Exchange Commission on August 03, 2026, disclosing a material event.
8k filedNASDAQ:DSGN
Design Therapeutics, Inc. (DSGN) Reports Material Event to SEC
Filing Details Design Therapeutics, Inc. (NASDAQ:DSGN) filed a Form 8-K with the Securities and Exchange Commission on August 03, 2026, disclosing a material event. Market Context…
Market Context
Design Therapeutics, Inc.'s stock currently trades at $12.76 with a market capitalization of $526.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Design Therapeutics, Inc.'s stock.
All SEC filings for Design Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View DSGN Stock Page
Frequently Asked Questions
Where can I read DSGN's SEC filings?
Browse all filings on our DSGN SEC filings page.
What types of SEC filings does Design Therapeutics, Inc. file?
Public companies like Design Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.